Skip to main content

Table 1 Accrual to whole brain radiotherapy trials

From: Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible

Trial Design Histology and no. of BMs Appropriate NCF testing Actual recruitment (patients/years) Average no. of patients accrued per year Total number of melanoma patients (%)
Patchell et al. [8] WBRT vs. OBS All solid tumours (mainly lung) Sol BM post- surgery No 96/8 years 12 2 (2%)
Aoyama et al. [9] SR vs. WBRT + SRS All solid tumours (mainly lung) 1–4 BMs No 132/4 years 33 Unknown
Kocher et al. [10] SR vs. SR + WBRT All solid tumours (mainly lung) 1–3 BMs No 359/11 years 33 18 (5%)
Chang et al. [11] SR vs. WBRT + SR All solid tumours (mainly lung) 1–3 BMs Yes 58/6 years 10 Early closure 7 patients (12%)
Roos et al. [12]* WBRT vs. OBS All solid tumours sol BM post-SR/surgery No 19/3 years 6 3 (16%)
This study WBRT vs. observation Melanoma only 1–3 BMs post-SR/surgery Yes 54/2 years 27 54 (100%)
  1. WBRT - Whole Brain Radiotherapy.
  2. SR - Stereotactic Radiosurgery.
  3. Sol BM - solitary Brain Metastases.
  4. OBS- observation.
  5. NCF - Neurocognitive.
  6. *Early closure due to poor accrual.